2016 Conference Access Set (Plenaries, Symposia & Workshops)


Standard: Free

Products

BB12: SW/PSYCH: Advocating for Patients in Education & Employment: Crucial Information

Preview Available

BB12: SW/PSYCH: Advocating for Patients in Education & Employment: Crucial Information

Oct 29, 2016 12:15pm ‐ Oct 29, 2016 1:35pm

The session will explore legal protections for children and adults with CF in the areas of education and employment. Best practices in assessing your patients situations and advocating for their rights will be discussed.

Educational Objectives:
  • Interpret employment law for the adult with CF.
  • Identify making parameters to consider and reduce work hours to optimize health.
  • Appraise your ability to educate your patients/families and academic advocacy tool kit by understanding academic law.

*** This session was streamed live during the 2016 NACFC. To watch free archived versions of the live streamed sessions, register here: https://arc.nacfconference.org/cff/live/16

Chair(s):
  • Al Lew, LICSW, Sr. Medical Social Worker
Speaker(s): Speaker(s):
Standard: $49.99

P1: A Cure for All: Leaving No One Behind

Preview Available

P1: A Cure for All: Leaving No One Behind

Oct 27, 2016 4:30pm ‐ Oct 27, 2016 6:00pm

This session will describe recent advances towards treatment of cystic fibrosis, and the pipeline for new and emerging therapies. Interventions that target important disease manifestations, emerging small molecules designed to overcome rare and fundamental defects in CFTR, and molecular repair of the CF gene will be discussed.

Educational Objectives:
  • Describe leading-edge programs directed towards cystic fibrosis palliation, including novel experimental therapies intended to overcome progressive tissue injury.
  • Compare and distinguish among major initiatives pursuing gene editing as a means to effectively treat a diversity of CF subclasses.
  • Summarize parallel development of experimental treatment strategies, and the prevailing rationale intended to advance new and effective therapies for the disease.
*** This session was streamed live during the 2016 NACFC. To watch free archived versions of the live streamed sessions, register here: https://arc.nacfconference.org/cff/live/16

Speaker(s):
Standard: $49.99

P2: Clinical Research: A Worldwide CF Community Effort

Preview Available

P2: Clinical Research: A Worldwide CF Community Effort

Oct 28, 2016 9:00am ‐ Oct 28, 2016 10:00am

The CF clinical trial pipeline is at present very busy and this is great news. This session will explain how worldwide collaboration and streamlining can optimize the efficiency in the clinical trial arena.

Educational Objectives:
  • Summarize information about clinical trial networks outside of the United States.
  • Calculate on the clinical trial pipeline in regions other than the United States.
  • Discuss how sharing information and standard operating procedures facilitate global clinical trials.

*** This session was streamed live during the 2016 NACFC. To watch free archived versions of the live streamed sessions, register here: https://arc.nacfconference.org/cff/live/16

Speaker(s):
Standard: $49.99

P3: You Can Observe A Lot by Just Watching: Lessons from The CFF Patient Registry

Preview Available

P3: You Can Observe A Lot by Just Watching: Lessons from The CFF Patient Registry

Oct 29, 2016 9:00am ‐ Oct 29, 2016 10:00am

This plenary session will review the role of observational research in improving our understanding of cystic fibrosis, the care of patients with cystic fibrosis and opportunities to improve this care. The speaker will highlight the role of the Cystic Fibrosis Foundation Patient Registry in the conduct and further development of observational research in CF including epidemiology, comparative effectiveness research, and quality improvement.

Educational Objectives:
  1. Define the role of observational research in improving our understanding of cystic fibrosis care and outcomes.
  2. Describe the role of the Cystic Fibrosis Foundation Patient Registry (CFFPR) in epidemiologic and comparative effectiveness research.
  3. Define the role of the CFFPR in quality improvement efforts.

*** This session was streamed live during the 2016 NACFC. To watch free archived versions of the live streamed sessions, register here: https://arc.nacfconference.org/cff/live/16

Speaker(s):
  • Wayne J. Morgan, M.D., Professor; CF Center Director, Univ. of AZ, Univ. Med. Ctr.
Standard: $49.99

S01: APP&D: Mucociliary Transport & Ion Flux: Lessons Learned From New Models & New Drugs

Preview Available

S01: APP&D: Mucociliary Transport & Ion Flux: Lessons Learned From New Models & New Drugs

Oct 27, 2016 2:00pm ‐ Oct 27, 2016 3:25pm

Mucociliary clearance and airway surface pH are each defined by CFTR and play key roles in CF lung pathophysiology. New data, animal models and CFTR modulating drugs offer unique opportunities to better understand the basic defects causing lung disease in patients. This symposium will review and integrate these data, allowing the participant to better understand the basis of new therapeutic approaches for CF lung disease.

Educational Objectives:
  • Discuss the importance of absorption, secretion and pH in CF lung pathophysiology.
  • Summarize innate immunity in the airways of healthy individuals and of people with CF.
  • Identify promising new therapeutic approaches addressing the basic defects in mucociliary clearance and host defenses in the CF airways.

Chair(s): Speaker(s):
Standard: $49.99

S02: CFTR: Understanding Missense & Misfolding Mutations in CFTR

Preview Available

S02: CFTR: Understanding Missense & Misfolding Mutations in CFTR

Oct 27, 2016 2:00pm ‐ Oct 27, 2016 3:25pm

This symposium aims to provide insights into the mechanisms how the most common CF mutations, categorized by the CFTR2 initiative, influence CFTR structure and function. This will be discussed in light of the CFTR 3D model, with a particular focus on structures of the nucleotide-binding domains (NBDs). Furthermore, this session will also discuss how the cellular proteome may deferentially process CF mutations.

Educational Objectives:
  • Describe the latest data on categorizing the CFTR2 database concerning trafficking, function and clinical manifestations.
  • Explain how CF mutations influence CFTR structure and function using 3D models of CFTR and structures of the NBDs.
  • Identify how mutation-specific interactome directs the fate of CFTR.

Speaker(s):
Standard: $49.99

S03: CLIN: Review of the New CF Diagnosis Consensus Guidelines

Preview Available

S03: CLIN: Review of the New CF Diagnosis Consensus Guidelines

Oct 27, 2016 2:00pm ‐ Oct 27, 2016 3:25pm

The diagnosis of CF has evolved over time as more information becomes available about CF genetics, outcomes associated with newborn screening, and new diagnostic techniques are developed. To reflect these changes, in October 2015 the CF Foundation sponsored a consensus conference to revise the diagnostic criteria for CF. The goal of this symposium is to review the key findings and recommendations from the conference.

Educational Objectives:
  • Describe the different categories of CFTR mutations in CFTR2.
  • Describe outcomes in infants with a positive CF newborn screen but inconclusive diagnostic testing.
  • Describe the role of ancillary studies in the diagnosis of CF.

Chair(s): Speaker(s):
Standard: $49.99

S04: INF/MIC: Non-tuberculous Mycobacteria: Now That the Guidelines Are Published

Preview Available

S04: INF/MIC: Non-tuberculous Mycobacteria: Now That the Guidelines Are Published

Oct 27, 2016 2:00pm ‐ Oct 27, 2016 3:25pm

Mycobacteria appears to be more prevalent in the CF population, and the prevalence of sub-species of sputum mycobacteria found are changing. The symposium addresses CF mycobacterial lung disease versus colonization, antibiotic treatment and duration of treatment. The issue of whether or not to proceed with lung transplantation in CF patients infected with mycobacteria is discussed. The molecular identification of various sub-species of mycobacteria and epidemiological implications is addressed.

Educational Objectives:
  • Summarize antibiotic susceptibility testing and monitoring treatment response of mycobacterial disease.
  • Evaluate if patients with M. abscessus should undergo lung transplantation.
  • Interpret mycobacteria strain genotyping.

Chair(s): Speaker(s):
Standard: $49.99

S05: NRS: Growing Older With CF

Preview Available

S05: NRS: Growing Older With CF

Oct 27, 2016 2:00pm ‐ Oct 27, 2016 3:25pm

As the median age of the Cystic Fibrosis patient is approaching forty years, Cystic Fibrosis patients are experiencing and developing 'adult' illness, responsibilities, comorbidities, and challenges of daily living and quality of life.

There are many challenging and unique concerns for the aging Cystic Fibrosis patient. This session will address four; the importance of sleep and its influence on health, posture, urinary incontinence and pelvic floor, when to begin routine screenings, such as bone density study, colonoscopy, mammograms, etc., and how to balance stressors that occur with chronic illness, comorbidities, family and careers.

Educational Objectives:
  • Learn the importance and benefits of good sleep, the challenges of obtaining restful sleep consistently, and how fatigue and insomnia can adversely affect health.
  • Recognize the older CF patient has unique health screenings added to their routine CF care such as colonoscopy, bone density study, mammogram, etc. and when such screenings should be added to 'annual' evaluations.
  • Recognize the adult CF patient has multiple challenges and stressors, balancing lifestyle, career, health, family.

*** This session was streamed live during the 2016 NACFC. To watch free archived versions of the live streamed sessions, register here: https://arc.nacfconference.org/cff/live/16

Chair(s): Speaker(s):
Standard: $49.99

S06: NT: CFTR Gene Repair & Replacement: New Progress Toward Cystic Fibrosis Therapy

Preview Available

S06: NT: CFTR Gene Repair & Replacement: New Progress Toward Cystic Fibrosis Therapy

Oct 27, 2016 2:00pm ‐ Oct 27, 2016 3:25pm

Future therapies for CF may involve direct replacement or repair of the CFTR gene in the airways of affected patients. This was the focus of several recent CFF RFAs. In order to develop effective therapies, improved vector delivery to the airway epithelium will be required; recent advances in improving airway specificity of viral vectors will be presented. Furthermore, recent technological advances now permit the site-specific repair of genes (such as CFTR) both ex vivo and in vivo; a recent example of in vivo correction of muscular dystrophy will be highlighted. Finally, basal cells play a crucial role in maintaining the airway epithelium; their potential for cellular therapy in CF will be discussed.

Educational Objectives:
  • Discuss potential gene and cell therapies for CF.
  • Identify technical challenges for development and delivery of such therapies.
  • Review how application of such approaches to other diseases may highlight issues relevant to application to CF.

Chair(s): Speaker(s):
Standard: $49.99